BR0310018A - Uso de valsartan ou seu metabólito para inibir agregação de plaqueta - Google Patents

Uso de valsartan ou seu metabólito para inibir agregação de plaqueta

Info

Publication number
BR0310018A
BR0310018A BR0310018-9A BR0310018A BR0310018A BR 0310018 A BR0310018 A BR 0310018A BR 0310018 A BR0310018 A BR 0310018A BR 0310018 A BR0310018 A BR 0310018A
Authority
BR
Brazil
Prior art keywords
metabolite
valsartan
platelet aggregation
ischemic
acute
Prior art date
Application number
BR0310018-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Alex Malinin
Victor Serebruany
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29423705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0310018(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0310018A publication Critical patent/BR0310018A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR0310018-9A 2002-05-14 2003-05-13 Uso de valsartan ou seu metabólito para inibir agregação de plaqueta BR0310018A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38037302P 2002-05-14 2002-05-14
US39501402P 2002-07-11 2002-07-11
PCT/EP2003/004997 WO2003094915A1 (en) 2002-05-14 2003-05-13 Use of valsartan ot its metabolite to inhibit platelet aggregation

Publications (1)

Publication Number Publication Date
BR0310018A true BR0310018A (pt) 2005-02-15

Family

ID=29423705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0310018-9A BR0310018A (pt) 2002-05-14 2003-05-13 Uso de valsartan ou seu metabólito para inibir agregação de plaqueta

Country Status (22)

Country Link
US (2) US20050197372A1 (https=)
EP (1) EP1505965B1 (https=)
JP (1) JP4467427B2 (https=)
KR (1) KR101005367B1 (https=)
CN (1) CN100408035C (https=)
AT (1) ATE334677T1 (https=)
AU (1) AU2003267447B8 (https=)
BR (1) BR0310018A (https=)
CA (1) CA2482541A1 (https=)
CY (1) CY1105638T1 (https=)
DE (1) DE60307265T2 (https=)
DK (1) DK1505965T3 (https=)
ES (1) ES2268403T3 (https=)
IL (2) IL164774A0 (https=)
MX (1) MXPA04011282A (https=)
NO (1) NO20045245L (https=)
NZ (1) NZ536295A (https=)
PL (1) PL371728A1 (https=)
PT (1) PT1505965E (https=)
RU (1) RU2334512C2 (https=)
TW (1) TWI299663B (https=)
WO (1) WO2003094915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
US10478404B2 (en) 2014-01-24 2019-11-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Materials, methods and devices for altering cell reactivity
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法
CN111643557B (zh) * 2020-05-26 2022-02-22 四川省骨科医院 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312198T1 (de) * 1993-04-05 2005-12-15 Univ Utah Res Found Diagnose und behandlung von supravalvular aortic stenosis
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
CA2379666C (en) * 1999-07-21 2009-10-13 Takeda Chemical Industries, Ltd. Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
AU2001267404A1 (en) * 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate

Also Published As

Publication number Publication date
AU2003267447A1 (en) 2003-11-11
KR20050000532A (ko) 2005-01-05
JP4467427B2 (ja) 2010-05-26
ATE334677T1 (de) 2006-08-15
DE60307265T2 (de) 2007-07-19
CN1652774A (zh) 2005-08-10
HK1074395A1 (en) 2005-11-11
PL371728A1 (en) 2005-06-27
CY1105638T1 (el) 2010-12-22
TW200410686A (en) 2004-07-01
AU2003267447B8 (en) 2009-08-06
NZ536295A (en) 2006-12-22
US20100048654A1 (en) 2010-02-25
JP2005529913A (ja) 2005-10-06
PT1505965E (pt) 2006-11-30
MXPA04011282A (es) 2005-01-25
AU2003267447B2 (en) 2006-11-02
WO2003094915A1 (en) 2003-11-20
CA2482541A1 (en) 2003-11-20
KR101005367B1 (ko) 2010-12-30
IL164774A0 (en) 2005-12-18
DK1505965T3 (da) 2006-11-13
EP1505965A1 (en) 2005-02-16
RU2334512C2 (ru) 2008-09-27
RU2004136583A (ru) 2005-09-10
IL164774A (en) 2010-04-29
US20050197372A1 (en) 2005-09-08
ES2268403T3 (es) 2007-03-16
DE60307265D1 (de) 2006-09-14
CN100408035C (zh) 2008-08-06
TWI299663B (en) 2008-08-11
EP1505965B1 (en) 2006-08-02
NO20045245L (no) 2004-11-30

Similar Documents

Publication Publication Date Title
BR0310018A (pt) Uso de valsartan ou seu metabólito para inibir agregação de plaqueta
RU2008120295A (ru) Средства и способы для лечения нарушений свертываемости
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
Bortolotti et al. New tools for optimizing fluid resuscitation in acute pancreatitis
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
RU2017124150A (ru) Производное дигидроиндолизинона
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2018502137A5 (https=)
WO2004004664A3 (en) Methods for treating or preventing ischemic injury
EA200300844A1 (ru) Использование ингибиторов il-18 для лечения и/или профилактики заболевания сердца
Fridlender et al. Myocardial infarction in a patient with β‐thalassemia major: First report
WO2005037230A3 (en) Compositions and methods for treating heart failure
DK1557414T3 (da) IsoquinoIin-forbindelser og medicinsk anvendelse deraf
WO2024249254A3 (en) Methods of using apol1 inhibitors
JP2021529189A5 (https=)
JP2005529913A5 (https=)
Mahajan et al. Synergistic antimalarial activity of ketones with rufigallol and vitamin C
Rawat et al. Dengue fever in a patient recovering from coronary artery bypass grafting
RU2004102562A (ru) Способ лечения ограниченной склеродермии
BRPI0508054A (pt) bloqueadores kv1.5 para o aumento seletivo da contratilidade auricular e tratamento da insuficiência cardìaca
Sandler et al. The delayed microembolism syndrome: A review of 84 deaths
RU2005113347A (ru) Способ лечения больных острым тромбофлебитом глубоких вен нижних конечностей
RU2002101166A (ru) Способ лечения тромбозов вен сетчатки с помощью доноров и ингибиторов оксида азота
EP2202293A3 (fr) Nouveaux composés actifs mutactimycines et aldgamycines et leur utilisation thérapeutique
Glancy et al. Headaches of increasing intensity for a week after using crack cocaine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.